A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Subjects With Severely Impaired Renal Function
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs AMG 986 (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Amgen
- 14 Mar 2018 Planned End Date changed from 26 Jun 2018 to 28 Jun 2018.
- 14 Mar 2018 Planned primary completion date changed from 26 Jun 2018 to 5 Apr 2018.
- 14 Mar 2018 Status changed from recruiting to active, no longer recruiting.